Liposomes containing the imiquimod adjuvant as a vaccine in the cutaneous leishmaniasis model

Authors

  • Ahmad Mehravaran Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis institute, Zahedan University of Medical Sciences, Zahedan, Iran|Department of Parasitology and Mycology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
  • Hadi Mirahmadi Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis institute, Zahedan University of Medical Sciences, Zahedan, Iran|Department of Parasitology and Mycology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
  • Javad Akhtari Toxoplasmosis Research Center, Department of Medical Nanotechnology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Abstract:

Objective(s): Attempts to produce vaccines for leishmaniasis need adjuvants to trigger the kind of immune reaction required for protection. In this study, we examined the properties of the TLR7 agonist imiquimod, a vaccine adjuvant, making use of a live model of infection where the immune reactions could be identified prior to and following the challenge of infection. Materials and Methods: The liposomes of EPC containing the imiquimod adjuvant were prepared and characterized for protein concentration, surface charge, and particle size. Vaccination was done using the soluble Leishmania antigen (SLA) as a first-generation vaccine model in the liposomal state to vaccinate BALB/c mice against the challenge of leishmania major. BALB/c mice were vaccinated subcutaneously, three times at a two-week interval. Parasite burden, footpad swelling, IgG isotype, as well as the level of IL-4 and IFN-γ were assessed as the protection criteria.Results: The group of mice vaccinated by Lip+Imiquimod+SLA demonstrated a lower amount of footpad swelling and parasite burden than the buffer group. In addition, the highest level of IFN-γ and the lowest level of IL-4 production was noticed in the splenocytes of the mice vaccinated with the formulation of Lip+Imiquimod+SLA. Conclusion: These results imply that imiquimod added to the formulation of liposomes is able to modulate the immune reaction of the BALB/c mice vaccinated preferably to a Th1 reaction rather than a Th2 reaction which can also lead to partial protection against the challenge of Leishmania.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice

Objective(s): Protection against leishmaniasis, in the murine model, is dependent on developing a potent CD4+ mediated Th1 type response. Liposomes can be applied as immunoadjuvants to stimulate immune responses to different antigens. In the present study, it was investigated whether DOTAP liposomes having SLA and imiquimod adjuvant, can induce a Th1 response and prote...

full text

the significance of conjunction as a cohesive device in teaching writing

the research questions were as follows: 1. is there any relationship between the students concious awareness of the form and implications of the conjuncations and their improvement in using appropriate conjunctions? 2. does students knowledge of the from and the implications of the conjunctions help them to produce more coherent writings. 3. does a comparison between english conjunctions and th...

15 صفحه اول

Efficacy of topical 5% imiquimod with cryotherapy versus intralesional meglumine antimoniate in the treatment of anthroponotic cutaneous leishmaniasis

Background: Cutaneous leishmaniasis (CL) is a major world problem. Several types of treatment regimens have been suggested. Imiquimod demonstrated a leishmanicidal activity by increasing local cytokine production. The aim of this study was to determine the efficacy of topical 5% imiquimod with cryotherapy vs. intralesional meglumine antimoniate (MA) in treatment of anthroponotic (dry type) CL. ...

full text

Liposomes as adjuvant for anti-mycobacterial vaccine development.

Mycobacteria are intracellular pathogens that invade and reside inside the macrophages. Recent advances in controlled delivery systems for vaccines such as liposomes have sparked a renewed interest in their potential application for the prevention of mycobacterial infections. The versatility of liposomes in the incorporation of hydrophilic/hydrophobic components, their non-toxic nature, biodegr...

full text

Optimization of a Method to Prepare Liposomes Containing HER2/Neu-Derived Peptide as a Vaccine Delivery System for Breast Cancer

The purpose of this study was to optimize a method for the encapsulation of P5 peptide, a new designed peptide containing MHC class I epitopes from rat HER2/neu protein, into liposomes as an approach for breast cancer vaccine formulation. The efficiency of liposomal encapsulation of peptides is generally low and development of an optimized method to increase encapsulation efficiency is a big ch...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 7  issue 1

pages  29- 39

publication date 2020-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023